This suggests a potential interaction between c-MET inhibition and immune evasion, providing a theoretical basis for combining a c-MET inhibitor with immune checkpoint blockade in the treatment of NSCLC [198]. This evidence concerns the gene MET and non-small cell lung carcinoma.